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Objectives: This article has two main objectives. One is to examine the 
correspondence between World Bank pharmaceutical policies in Latin America 
and recommendations made in World Bank documents, and the other is to 
analyze the implementation of these recommendations.  
Methodology: Bibliographical and document review, and in-depth interviews. 
Results: The authors claim that health care systems spend a relatively high 
percentage of their resources on purchasing drugs, while the poor spend a 
disproportionate segment of their income on drugs. There is ample evidence in 
the literature that these medicines are poorly utilized. The explicit goals of the 
reforms led by the World Bank were to improve equity, efficiency, quality, and 
user satisfaction --difficult goals to achieve if medications are not affordable.  
The authors found that the World Bank identified and recommended a set of 
suitable measures to be taken to meet Latin America's pharmaceutical needs. 
They note that these recommendations were, however, ignored in the reforms 
supported by the World Bank and that the majority of loans that included 
pharmaceutical measures allocated funds only for drug purchases. The authors 
propose four hypotheses for understanding the World Bank’s failure to support its 
recommendations: 1) a lack of pharmaceutical experts with influence in the World 
Bank; 2) the World Bank's tendency to exclude interventions not related to 
infrastructure, institutional development, or equipment purchases; 3) opposition 
by countries to financing pharmaceutical interventions; 4) the liberal ideology of 
World Bank policy decision-makers. The authors analyze these hypotheses, but 
conclude that it is difficult for external researchers to verify their validity, given the 
Bank’s lack of transparency.  
Conclusions: The pharmaceutical needs of Latin America’s health systems 
correspond closely to those expressed in the 1993 World Bank Report which 
dealt with the need to rationalize drug expenditures and use. This would include 
improving production, prescribing, dispensing, consumption, and industry 
regulation --areas that require technical help. The WHO contributes to some 
extent, but its resources are limited. World Bank loans could be used to 
complement WHO efforts.  
 
